Question 1

What is NeuroSense Therapeutics?

Accepted Answer

NeuroSense Therapeutics is a Entity.

Question 2

How often does NeuroSense Therapeutics appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was NeuroSense Therapeutics first tracked by Ergen?

Accepted Answer

First tracked on Jun 02, 2026.

Question 4

When was NeuroSense Therapeutics last mentioned in news?

Accepted Answer

Last active on Jul 01, 2026.

Question 5

What is NeuroSense Therapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is NeuroSense Therapeutics in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving NeuroSense Therapeutics?

Accepted Answer

NeuroDex ExoSORT ALS Biomarker Breakthrough (Jul 01, 2026, 6 articles).

Question 8

How did the "NeuroDex ExoSORT ALS Biomarker Breakthrough" event impact NeuroSense Therapeutics?

Accepted Answer

NeuroSense Therapeutics conducted the PARADIGM clinical trial where NeuroDex's ExoSORT workflow was applied, demonstrating the effectiveness of its drug candidate PrimeC in reducing NDE-associated TDP-43.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.